E. Maher, J. Yates, R. Harries, C. Benjamin, R. Harris et al., Clinical Features and Natural History of von Hippel-Lindau Disease, QJM, vol.77, issue.2, pp.1151-63, 1990.
DOI : 10.1093/qjmed/77.2.1151

R. Lonser, G. Glenn, M. Walther, E. Chew, S. Libutti et al., von Hippel-Lindau disease, The Lancet, vol.361, issue.9374, pp.2059-67, 2003.
DOI : 10.1016/S0140-6736(03)13643-4

S. Richard, J. Graff, J. Lindau, and F. Resche, Von Hippel-Lindau disease, The Lancet, vol.363, issue.9416, pp.1231-1235, 2004.
DOI : 10.1016/S0140-6736(04)15957-6
URL : https://hal.archives-ouvertes.fr/inserm-01402348

K. Jr and W. , Molecular basis of the VHL hereditary cancer syndrome, Nature Reviews Cancer, vol.2, pp.673-82, 2002.

H. Cohen and F. Mcgovern, Renal-Cell Carcinoma, New England Journal of Medicine, vol.353, issue.23, pp.2477-90, 2005.
DOI : 10.1056/NEJMra043172

B. Rini, S. Campbell, and B. Escudier, Renal cell carcinoma, The Lancet, vol.373, issue.9669, pp.1119-1151, 2009.
DOI : 10.1016/S0140-6736(09)60229-4

K. Jr and W. , The von Hippel?Lindau tumour suppressor protein: O2 sensing and cancer, Nature Reviews Cancer, vol.8, pp.865-73, 2008.

E. Maher, H. Neumann, and S. Richard, von Hippel???Lindau disease: A clinical and scientific review, European Journal of Human Genetics, vol.62, issue.6, pp.617-640, 2011.
DOI : 10.2174/1566524043359827
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110036

H. Neumann, H. Eggert, R. Scheremet, M. Schumacher, M. Mohadjer et al., Central nervous system lesions in von Hippel-Lindau syndrome., Journal of Neurology, Neurosurgery & Psychiatry, vol.55, issue.10, pp.898-901, 1992.
DOI : 10.1136/jnnp.55.10.898

S. Richard, P. David, K. Marsot-dupuch, C. Béroud, S. Giraud et al., Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease, Neurosurgical Review, vol.23, issue.1, pp.1-22, 2000.
DOI : 10.1007/s101430050024

J. Wanebo, R. Lonser, G. Glenn, and E. Oldfield, The natural history of hemangioblastomas of the central nervous system in patients with von Hippel???Lindau disease, Journal of Neurosurgery, vol.98, issue.1, pp.82-94, 2003.
DOI : 10.3171/jns.2003.98.1.0082

R. Lonser, A. Vortmeyer, J. Butman, S. Glasker, M. Finn et al., Edema is a precursor to central nervous system peritumoral cyst formation, Annals of Neurology, vol.136, issue.3, pp.392-401, 2005.
DOI : 10.1002/ana.20584

J. Wind and R. Lonser, Management of von Hippel???Lindau disease-associated CNS lesions, Expert Review of Neurotherapeutics, vol.11, issue.10, pp.1433-1474, 2011.
DOI : 10.1586/ern.11.124

A. Webster, E. Maher, and A. Moore, Clinical Characteristics of Ocular Angiomatosis in von Hippel-Lindau Disease and Correlation With Germline Mutation, Archives of Ophthalmology, vol.117, issue.3, pp.371-379, 1999.
DOI : 10.1001/archopht.117.3.371

H. Dollfus, P. Massin, P. Taupin, C. Nemeth, S. Amara et al., Ocular manifestations in von Hippel?Lindau disease: a clinical and molecular study, Investigative Ophthalmology and Visual Science, vol.43, pp.3067-74, 2002.

A. Gaudric, V. Krivosic, G. Duguid, P. Massin, S. Giraud et al., Vitreoretinal Surgery for Severe Retinal Capillary Hemangiomas in Von Hippel???Lindau Disease, Ophthalmology, vol.118, issue.1, pp.142-151, 2011.
DOI : 10.1016/j.ophtha.2010.04.031

H. Neumann, B. Bender, D. Berger, J. Laubenberger, W. Schultze-seemann et al., PREVALENCE, MORPHOLOGY AND BIOLOGY OF RENAL CELL CARCINOMA IN VON HIPPEL-LINDAU DISEASE COMPARED TO SPORADIC RENAL CELL CARCINOMA, The Journal of Urology, vol.160, issue.4, pp.1248-54, 1998.
DOI : 10.1016/S0022-5347(01)62509-6

D. Chauveau, C. Duvic, Y. Chrétien, F. Paraf, D. Droz et al., Renal involvement in von Hippel-Lindau disease, Kidney International, vol.50, issue.3, pp.944-51, 1996.
DOI : 10.1038/ki.1996.395

F. Steinbach, A. Novick, H. Zincke, D. Miller, R. Williams et al., Treatment of Renal Cell Carcinoma in Von Hippel-Lindau Disease: A Multicenter Study, The Journal of Urology, vol.153, issue.6, pp.1812-1818, 1995.
DOI : 10.1016/S0022-5347(01)67318-X

J. Herring, E. Enquist, A. Chernoff, W. Linehan, P. Choyke et al., PARENCHYMAL SPARING SURGERY IN PATIENTS WITH HEREDITARY RENAL CELL CARCINOMA: 10-YEAR EXPERIENCE, The Journal of Urology, vol.165, issue.3, pp.777-81, 2001.
DOI : 10.1016/S0022-5347(05)66524-X

M. Rouprêt, V. Hopirtean, A. Mejean, N. Thiounn, B. Dufour et al., Nephron Sparing Surgery for Renal Cell Carcinoma and von Hippel-Lindau???s Disease: A Single Center Experience, The Journal of Urology, vol.170, issue.5, pp.1752-5811, 2003.
DOI : 10.1097/01.ju.0000092780.85876.de

B. Duffey, P. Choyke, G. Glenn, R. Grubb, D. Venzon et al., THE RELATIONSHIP BETWEEN RENAL TUMOR SIZE AND METASTASES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE, The Journal of Urology, vol.172, issue.1, pp.63-68, 2004.
DOI : 10.1097/01.ju.0000132127.79974.3f

W. Shingleton and P. Sewell, PERCUTANEOUS RENAL CRYOABLATION OF RENAL TUMORS IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE, The Journal of Urology, vol.167, issue.3, pp.1268-70, 2002.
DOI : 10.1016/S0022-5347(05)65279-2

B. Yang, R. Autorino, E. Remer, H. Laydner, S. Hillyer et al., Probe ablation as salvage therapy for renal tumors in von Hippel-Lindau patients: The Cleveland Clinic experience with 3 years follow-up, Urologic Oncology: Seminars and Original Investigations, vol.31, issue.5, 2011.
DOI : 10.1016/j.urolonc.2011.05.008

D. Joly, A. Méjean, J. Corréas, M. Timsit, S. Deveaux et al., Progress in Nephron Sparing Therapy for Renal Cell Carcinoma and von Hippel-Lindau Disease, The Journal of Urology, vol.185, issue.6, pp.2056-60, 2011.
DOI : 10.1016/j.juro.2011.02.007

D. Goldfarb, H. Neumann, I. Penn, and A. Novick, RESULTS OF RENAL TRANSPLANTATION IN PATIENTS WITH RENAL CELL CARCINOMA AND VON HIPPEL-LINDAU DISEASE1,2, Transplantation, vol.64, issue.12, pp.1726-1735, 1997.
DOI : 10.1097/00007890-199712270-00017

S. Richard, C. Beigelman, J. Duclos, J. Fendler, H. Plauchu et al., Pheochromocytoma as the first manifestation of von Hippel?Lindau disease, Surgery, vol.116, pp.1076-81, 1994.

M. Walther, R. Reiter, H. Keiser, P. Choyke, D. Venzon et al., CLINICAL AND GENETIC CHARACTERIZATION OF PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU FAMILIES: COMPARISON WITH SPORADIC PHEOCHROMOCYTOMA GIVES INSIGHT INTO NATURAL HISTORY OF PHEOCHROMOCYTOMA, The Journal of Urology, vol.162, issue.3, pp.659-64, 1999.
DOI : 10.1097/00005392-199909010-00004

C. Boedeker, Z. Erlic, S. Richard, U. Kontny, A. Gimenez-roqueplo et al., Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.6, pp.1938-1982, 2009.
DOI : 10.1210/jc.2009-0354
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690424

G. Eisenhofer, M. Walther, T. Huynh, S. Li, S. Bornstein et al., Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.5, pp.1999-2008, 2001.
DOI : 10.1210/jcem.86.5.7496

G. Eisenhofer, J. Lenders, W. Linehan, M. Walther, D. Goldstein et al., Plasma Normetanephrine and Metanephrine for Detecting Pheochromocytoma in von Hippel???Lindau Disease and Multiple Endocrine Neoplasia Type 2, New England Journal of Medicine, vol.340, issue.24, pp.1872-1881, 1999.
DOI : 10.1056/NEJM199906173402404

M. Baghai, G. Thompson, Y. Jr, W. Grant, C. Grant et al., Pheochromocytomas and Paragangliomas in von Hippel???Lindau Disease, Archives of Surgery, vol.137, issue.6, pp.682-690, 2002.
DOI : 10.1001/archsurg.137.6.682

J. Blansfield, L. Choyke, S. Morita, P. Choyke, J. Pingpank et al., Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs), Surgery, vol.142, issue.6, pp.814-822, 2007.
DOI : 10.1016/j.surg.2007.09.012

O. Corcos, A. Couvelard, S. Giraud, M. Vullierme, O. Toole et al., Endocrine Pancreatic Tumors in von Hippel-Lindau Disease, Pancreas, vol.37, issue.1, pp.85-93, 2008.
DOI : 10.1097/MPA.0b013e31815f394a

P. Hammel, V. Vilgrain, B. Terris, F. Penfornis, A. Sauvanet et al., Pancreatic involvement in von Hippel???Lindau disease, Pancreatic involvement in von Hippel?Lindau disease, pp.1087-95, 2000.
DOI : 10.1053/gast.2000.18143

T. Manski, D. Heffner, G. Glenn, N. Patronas, A. Pikus et al., Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease, JAMA: The Journal of the American Medical Association, vol.277, issue.18, pp.1461-1467, 1997.
DOI : 10.1001/jama.277.18.1461

D. Choo, L. Shotland, M. Mastroianni, G. Glenn, C. Van-waes et al., Endolymphatic sac tumors in von Hippel???Lindau disease, Journal of Neurosurgery, vol.100, issue.3, pp.480-487, 2004.
DOI : 10.3171/jns.2004.100.3.0480

H. Neumann and O. Wiestler, Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus, The Lancet, vol.337, issue.8749, pp.1052-1056, 1991.
DOI : 10.1016/0140-6736(91)91705-Y

E. Maher, A. Webster, F. Richards, J. Green, P. Crossey et al., Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations., Journal of Medical Genetics, vol.33, issue.4, pp.328-360, 1996.
DOI : 10.1136/jmg.33.4.328
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1050584

C. Lammens, E. Bleiker, S. Verhoef, F. Hes, M. Ausems et al., Psychosocial impact of Von Hippel-Lindau disease: levels and sources of distress, Clinical Genetics, vol.288, issue.23, pp.483-91, 2010.
DOI : 10.1111/j.1399-0004.2010.01333.x

B. Seizinger, G. Rouleau, L. Ozelius, A. Lane, G. Farmer et al., Von Hippel???Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma, Nature, vol.332, issue.6161, pp.268-277, 1988.
DOI : 10.1038/332268a0

F. Latif, K. Tory, J. Gnarra, M. Yao, F. Duh et al., Identification of the von Hippel-Lindau disease tumor suppressor gene, Science, vol.260, issue.5112, pp.1317-1337, 1993.
DOI : 10.1126/science.8493574

W. Kim and W. Kaelin, Gene Mutation in Human Cancer, Journal of Clinical Oncology, vol.22, issue.24, pp.4991-5004, 2004.
DOI : 10.1200/JCO.2004.05.061

C. Stebbins, K. Jr, W. Pavletich, and N. , Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function, Science, vol.284, issue.5413, pp.455-61, 1999.
DOI : 10.1126/science.284.5413.455

P. Maxwell, M. Wiesener, G. Chang, S. Clifford, E. Vaux et al., The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis, Nature, vol.399, pp.271-276, 1999.

K. Jr, W. Ratcliffe, and P. , Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway, Molecular Cell, vol.30, pp.393-402, 2008.

M. Ohh, C. Park, M. Ivan, M. Hoffman, T. Kim et al., Ubiquitination of HIF requires direct binding to the von Hippel?Lindau protein domain, Nature Cell Biology, vol.2, pp.423-430, 2000.

M. Ivan, K. Kondo, H. Yang, W. Kim, J. Valiando et al., HIFalpha Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing, Science, vol.292, issue.5516, pp.464-472, 2001.
DOI : 10.1126/science.1059817

P. Jaakkola, D. Mole, Y. Tian, M. Wilson, J. Gielbert et al., Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation, Science, vol.292, issue.5516, pp.468-72, 2001.
DOI : 10.1126/science.1059796

R. Bruick and S. Mcknight, A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF, Science, vol.294, issue.5545, pp.1337-1377, 2001.
DOI : 10.1126/science.1066373

V. Singla and J. Reiter, The Primary Cilium as the Cell's Antenna: Signaling at a Sensory Organelle, Science, vol.313, issue.5787, pp.629-662, 2006.
DOI : 10.1126/science.1124534

B. Yolder, Role of Primary Cilia in the Pathogenesis of Polycystic Kidney Disease, Journal of the American Society of Nephrology, vol.18, issue.5, pp.1381-1389, 2007.
DOI : 10.1681/ASN.2006111215

A. Hergovich, J. Lisztwan, R. Barry, P. Ballschmieter, and W. Krek, Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL, Nature Cell Biology, vol.10, issue.1, pp.64-70, 2003.
DOI : 10.1093/emboj/17.2.368

M. Esteban, S. Harten, M. Tran, and P. Maxwell, Formation of Primary Cilia in the Renal Epithelium Is Regulated by the von Hippel-Lindau Tumor Suppressor Protein, Journal of the American Society of Nephrology, vol.17, issue.7, pp.1801-1807, 2006.
DOI : 10.1681/ASN.2006020181

M. Lutz and R. Burk, Primary Cilium Formation Requires von Hippel-Lindau Gene Function in Renal-Derived Cells, Cancer Research, vol.66, issue.14, pp.6903-6910, 2006.
DOI : 10.1158/0008-5472.CAN-06-0501

C. Thoma, A. Matov, K. Gutbrodt, C. Hoerner, Z. Smole et al., Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability, The Journal of Cell Biology, vol.23, issue.6, pp.991-1003, 2010.
DOI : 10.1083/jcb.201006059.dv

M. Ohh, R. Yauch, K. Lonergan, J. Whaley, A. Stemmer-rachamimov et al., The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix, Molecular Cell, vol.1, issue.7, pp.959-68, 1998.
DOI : 10.1016/S1097-2765(00)80096-9

G. Kurban, E. Duplan, N. Ramlal, V. Hudon, Y. Sado et al., Collagen matrix assembly is driven by the interaction of von Hippel???Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2, Oncogene, vol.2, issue.7, pp.1004-1016, 2008.
DOI : 10.1128/MCB.24.8.3251-3261.2004

M. Esteban-barragan, P. Avila, M. Alvarez-tejado, M. Gutiérrez, A. García-pardo et al., Role of the von Hippel?Lindau tumor suppressor gene in the formation of 1-integrin fibrillar adhesions, Cancer Research, vol.62, pp.2929-2965, 2002.

S. Lee, E. Nakamura, H. Yang, W. Wei, M. Linggi et al., Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer, Cancer Cell, vol.8, issue.2, pp.155-67, 2005.
DOI : 10.1016/j.ccr.2005.06.015
URL : http://doi.org/10.1016/j.ccr.2005.06.015

H. Yang, Y. Minamishima, Q. Yan, S. Schlisio, B. Ebert et al., pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-??B Agonist Card9 by CK2, Molecular Cell, vol.28, issue.1, pp.15-27, 2007.
DOI : 10.1016/j.molcel.2007.09.010

J. Roe, H. Kim, S. Lee, S. Kim, E. Cho et al., p53 Stabilization and Transactivation by a von Hippel-Lindau Protein, Molecular Cell, vol.22, issue.3, pp.395-405, 2006.
DOI : 10.1016/j.molcel.2006.04.006
URL : http://doi.org/10.1016/j.molcel.2006.04.006

J. Roe, H. Kim, I. Hwang, N. Ha, S. Kim et al., Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation, Cell Cycle, vol.10, issue.22, pp.3920-3928, 2011.
DOI : 10.4161/cc.10.22.18096

E. Maher, J. Yates, and M. Ferguson-smith, Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma., Journal of Medical Genetics, vol.27, issue.5, pp.311-315, 1990.
DOI : 10.1136/jmg.27.5.311

A. Prowse, A. Webster, F. Richards, S. Richard, S. Olschwang et al., Somatic inactivation of the VHL gene in von Hippel?Lindau disease tumours, American Journal of Human Genetics, vol.60, pp.765-71, 1997.

O. Iliopoulos, A. Kibel, S. Gray, and W. Kaelin, Tumour suppression by the human von Hippel-Lindau gene product, Nature Medicine, vol.162, issue.8, pp.822-828, 1995.
DOI : 10.1038/nm0895-822

K. Kondo, J. Klco, E. Nakamura, M. Lechpammer, K. Jr et al., Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein, Cancer Cell, vol.1, issue.3, pp.237-283, 2002.
DOI : 10.1016/S1535-6108(02)00043-0

J. Gnarra, K. Toty, Y. Weng, L. Schmidt, M. Wei et al., Mutations of the VHL tumour suppressor gene in renal carcinoma, Nature Genetics, vol.88, issue.1, pp.85-90, 1994.
DOI : 10.1038/ng0594-85

A. Vortmeyer, J. Gnarra, M. Emmert-buck, D. Katz, W. Linehan et al., von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease, Human Pathology, vol.28, issue.5, pp.540-543, 1997.
DOI : 10.1016/S0046-8177(97)90075-7

D. Park, Z. Zhuang, L. Chen, N. Szerlip, I. Maric et al., von Hippel-Lindau Disease-Associated Hemangioblastomas Are Derived from Embryologic Multipotent Cells, PLoS Medicine, vol.209, issue.2, p.60, 2007.
DOI : 10.1371/journal.pmed.0040060.g005
URL : http://doi.org/10.1371/journal.pmed.0040060

S. Mandriota, K. Turner, D. Davies, P. Murray, N. Morgan et al., HIF activation identifies early lesions in VHL kidneys, Cancer Cell, vol.1, issue.5, pp.459-68, 2002.
DOI : 10.1016/S1535-6108(02)00071-5
URL : http://doi.org/10.1016/s1535-6108(02)00071-5

M. Montani, K. Heinimann, A. Von-teichman, T. Rudolph, A. Perren et al., VHL-gene Deletion in Single Renal Tubular Epithelial Cells and Renal Tubular Cysts: Further Evidence for a Cyst-dependent Progression Pathway of Clear Cell Renal Carcinoma in von Hippel-Lindau Disease, The American Journal of Surgical Pathology, vol.34, issue.6, pp.806-821, 2010.
DOI : 10.1097/PAS.0b013e3181ddf54d

J. Maranchie, J. Vasselli, J. Riss, J. Bonifacino, W. Linehan et al., The contribution of VHL substrate binding and HIF1-?? to the phenotype of VHL loss in renal cell carcinoma, Cancer Cell, vol.1, issue.3, pp.247-55, 2002.
DOI : 10.1016/S1535-6108(02)00044-2

R. Raval, K. Lau, M. Tran, H. Sowter, S. Mandriota et al., Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma, Molecular and Cellular Biology, vol.25, issue.13, pp.5675-86, 2005.
DOI : 10.1128/MCB.25.13.5675-5686.2005

K. Kondo, W. Kim, M. Lechpammer, W. G. Kaelin, and . Jr, Inhibition of HIF2?? Is Sufficient to Suppress pVHL-Defective Tumor Growth, PLoS Biology, vol.146, issue.3, p.83, 2003.
DOI : 10.1371/journal.pbio.0000083.g004

W. Lim and W. Kaelin, Role of VHL gene mutation in human cancer, Journal of Clinical Oncology, vol.22, pp.4991-5004, 2004.

R. Banks, P. Tirukonda, C. Taylor, N. Hornigold, D. Astuti et al., Genetic and Epigenetic Analysis of von Hippel-Lindau (VHL) Gene Alterations and Relationship with Clinical Variables in Sporadic Renal Cancer, Cancer Research, vol.66, issue.4, pp.2000-2011, 2006.
DOI : 10.1158/0008-5472.CAN-05-3074

R. Beroukhim, J. Brunet, D. Napoli, A. Mertz, K. Seeley et al., Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney, Cancer Research, vol.69, issue.11, pp.4674-81, 2009.
DOI : 10.1158/0008-5472.CAN-09-0146

S. Shuib, W. Wei, H. Sur, M. Morris, D. Mcmullan et al., Copy number profiling in von hippel-lindau disease renal cell carcinoma, Genes, Chromosomes and Cancer, vol.70, issue.7, pp.479-88, 2011.
DOI : 10.1002/gcc.20865

I. Varela, P. Tarpey, K. Raine, D. Huang, C. Ong et al., Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma, Nature, vol.133, issue.7331, pp.539-581, 2011.
DOI : 10.1038/nature09639

G. Guo, Y. Gui, S. Gao, A. Tang, X. Hu et al., Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma, Nature Genetics, vol.44, issue.1, pp.17-26, 2011.
DOI : 10.1146/annurev.med.042808.171650

M. Purdue, M. Johansson, D. Zelenika, J. Toro, G. Scelo et al., Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3, Nature Genetics, vol.2, issue.1, pp.60-65, 2011.
DOI : 10.1186/1471-2105-11-134

S. Schlisio, R. Kenchappa, L. Vredeveld, R. George, R. Stewart et al., The kinesin KIF1B?? acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor, Genes & Development, vol.22, issue.7, pp.884-93, 2008.
DOI : 10.1101/gad.1648608

M. Nordstrom-o-'brien, R. Van-der-luijt, E. Van-rooijen, A. Van-den-ouweland, D. Majoor-krakauer et al., Genetic analysis of von Hippel?Lindau disease, Human Mutation, vol.31, pp.521-528, 2010.

B. Zbar, T. Kishida, F. Chen, E. Maher, F. Richards et al., Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan, Human Mutation, vol.25, issue.4, pp.348-57, 1996.
DOI : 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3

S. Olschwang, S. Richard, C. Boisson, S. Giraud, P. Laurent-puig et al., Germline mutation profile of the VHL gene in von Hippel???Lindau disease and in sporadic hemangioblastoma, Human Mutation, vol.12, issue.6, pp.424-454, 1998.
DOI : 10.1002/(SICI)1098-1004(1998)12:6<424::AID-HUMU9>3.3.CO;2-8

C. Stolle, G. Glenn, B. Zbar, J. Humphrey, P. Choyke et al., Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene, Human Mutation, vol.25, issue.6, pp.417-440, 1998.
DOI : 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K

C. Gallou, D. Chauveau, S. Richard, D. Joly, S. Giraud et al., Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions, Human Mutation, vol.8, issue.1, pp.215-239, 2004.
DOI : 10.1002/humu.20082

F. Hes, R. Van-der-luijt, A. Janssen, R. Zewald, G. De-jong et al., Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification, Clinical Genetics, vol.12, issue.2, pp.122-131, 2007.
DOI : 10.1111/j.1399-0004.2007.00827.x

K. Ong, E. Woodward, P. Killick, C. Lim, F. Macdonald et al., Genotype-phenotype correlations in von Hippel-Lindau disease, Human Mutation, vol.8, issue.2, pp.143-152, 2007.
DOI : 10.1002/humu.20385

C. Béroud, D. Joly, C. Gallou, F. Staroz, M. Orfanelli et al., Software and database for the analysis of mutations in the VHL gene, Nucleic Acids Research, vol.26, issue.1, pp.256-264, 1998.
DOI : 10.1093/nar/26.1.256

. Alu, Alu recombination underlies the vast majority of large VHL germline deletions: molecular characterization and correlations in VHL patients, Human Mutation, vol.30, pp.776-886, 2009.

M. Sgambati, C. Stolle, P. Choyke, M. Walther, B. Zbar et al., Mosaicism in von Hippel???Lindau Disease: Lessons from Kindreds with Germline Mutations Identified in Offspring with Mosaic Parents, The American Journal of Human Genetics, vol.66, issue.1, pp.84-91, 2000.
DOI : 10.1086/302726

H. Neumann, B. Bausch, S. Mcwhinney, B. Bender, O. Gimm et al., Germ-Line Mutations in Nonsyndromic Pheochromocytoma, New England Journal of Medicine, vol.346, issue.19, pp.1459-66, 2002.
DOI : 10.1056/NEJMoa020152

F. Hes, S. Mckee, M. Taphoorn, P. Rehal, R. Van-der-luijt et al., Cryptic von Hippel-Lindau disease: germline mutations in patients with haemangioblastoma only, Journal of Medical Genetics, vol.37, issue.12, pp.939-982, 2000.
DOI : 10.1136/jmg.37.12.939

H. Brauch, T. Kishida, D. Glavac, F. Chen, F. Pausch et al., Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect, Human Genetics, vol.95, issue.5, pp.551-557, 1995.
DOI : 10.1007/BF00223868

S. Clifford, M. Cockman, A. Smallwood, D. Mole, E. Woodward et al., Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease, Human Molecular Genetics, vol.10, issue.10, pp.1029-1067, 2001.
DOI : 10.1093/hmg/10.10.1029

M. Hoffman, M. Ohh, H. Yang, J. Klco, M. Ivan et al., von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF, Human Molecular Genetics, vol.10, issue.10, pp.1019-1046, 2001.
DOI : 10.1093/hmg/10.10.1019

A. Cascón, B. Escobar, C. Montero-conde, C. Rodríguez-antona, S. Ruiz-llorente et al., Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients, Human Mutation, vol.8, issue.6, pp.613-634, 2007.
DOI : 10.1002/humu.20496

P. Mettu, E. Agrón, S. Samtani, E. Chew, and W. Wong, Genotype-Phenotype Correlation in Ocular von Hippel-Lindau (VHL) Disease: The Effect of Missense Mutation Position on Ocular VHL Phenotype, Investigative Opthalmology & Visual Science, vol.51, issue.9, pp.4464-70, 2010.
DOI : 10.1167/iovs.10-5223

A. Webster, F. Richards, F. Macronald, A. Moore, and E. Maher, An Analysis of Phenotypic Variation in the Familial Cancer Syndrome von Hippel???Lindau Disease: Evidence for Modifier Effects, The American Journal of Human Genetics, vol.63, issue.4, pp.1025-1060, 1998.
DOI : 10.1086/302037

C. Ricketts, M. Zeegers, J. Lubinski, and E. Maher, Analysis of Germline Variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in Familial and Sporadic Renal Cell Carcinoma, PLoS ONE, vol.4, issue.6, p.6037, 2009.
DOI : 10.1371/journal.pone.0006037.t001

S. Ang, H. Chen, K. Hirota, V. Gordeuk, J. Jelinek et al., Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia, Nature Genetics, vol.59, issue.4, pp.614-635, 2002.
DOI : 10.1016/0167-4889(90)90126-X

E. Liu, M. Percy, C. Amos, Y. Guan, S. Shete et al., The worldwide distribution of the VHL 598C>T mutation indicates a single founding event, Blood, vol.103, issue.5, pp.1937-1977, 2004.
DOI : 10.1182/blood-2003-07-2550

R. Russell, R. Sufan, B. Zhou, P. Heir, S. Bunda et al., Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia, Nature Medicine, vol.90, issue.7, pp.845-54, 2011.
DOI : 10.1002/ajh.21381

K. Jr and W. , Treatment of kidney cancer; insights provided by the VHL tumor-suppressor protein, Cancer, vol.115, pp.2262-72, 2009.

W. Linehan, P. Pinto, G. Bratslavsky, E. Pfaffenroth, M. Merino et al., Hereditary kidney cancer, Cancer, vol.96, issue.suppl, pp.2252-61, 2009.
DOI : 10.1002/cncr.24230

L. Albiges, M. Salem, B. Rini, and B. Escudier, Vascular Endothelial Growth Factor???Targeted Therapies in Advanced Renal Cell Carcinoma, Hematology/Oncology Clinics of North America, vol.25, issue.4, pp.813-846, 2011.
DOI : 10.1016/j.hoc.2011.04.006

C. Jimenez, M. Cabanillas, L. Santarpia, E. Jonasch, K. Kyle et al., Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.2, pp.386-91, 2009.
DOI : 10.1210/jc.2008-1972

L. Aiello, D. George, M. Cahill, J. Wong, J. Cavallerano et al., Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416, Ophthalmology, vol.109, issue.9, pp.1745-51, 2002.
DOI : 10.1016/S0161-6420(02)01159-4

J. Girmens, A. Erginay, P. Massin, P. Scigalla, A. Gaudric et al., Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas, American Journal of Ophthalmology, vol.136, issue.1, pp.94-100, 2003.
DOI : 10.1016/S0002-9394(03)00101-6

S. Richard, L. Croisille, J. Yvart, N. Casadeval, P. Eschwège et al., Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy, Blood, vol.99, issue.10, pp.3851-3854, 2002.
DOI : 10.1182/blood.V99.10.3851

S. Madhusudan, G. Deplanque, J. Braybrooke, E. Cattell, M. Taylor et al., Antiangiogenic Therapy for von Hippel-Lindau Disease, JAMA: The Journal of the American Medical Association, vol.291, issue.8, pp.943-947, 2004.
DOI : 10.1001/jama.291.8.943

W. Wong, K. Liang, K. Hammel, H. Coleman, and E. Chew, Intravitreal Ranibizumab Therapy for Retinal Capillary Hemangioblastoma Related to von Hippel-Lindau Disease, Ophthalmology, vol.115, issue.11, pp.1957-64, 2008.
DOI : 10.1016/j.ophtha.2008.04.033
URL : http://doi.org/10.1016/j.ophtha.2008.04.033

E. Jonash, I. Mccutcheon, S. Waguespack, S. Wen, D. Davis et al., Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease, Annals of Oncology, vol.22, issue.12, pp.2661-2667, 2011.
DOI : 10.1093/annonc/mdr011

G. Chen, M. Karajannis, E. Newcomb, and D. Zagzag, Overexpression and activation of epidermal growth factor receptor in hemangioblastomas, Journal of Neuro-Oncology, vol.318, issue.2, pp.195-200, 2010.
DOI : 10.1007/s11060-010-0125-9

L. Whitesell and N. Lin, HSP90 as a platform for the assembly of more effective cancer chemotherapy, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1823, issue.3, pp.756-66, 2012.
DOI : 10.1016/j.bbamcr.2011.12.006

J. Kim, A. Kononenko, I. Erliandri, T. Kim, M. Nakano et al., Human artificial chromosome (HAC) vector with a conditional centromere for correction of genetic deficiencies in human cells, Proceedings of the National Academy of Sciences, vol.108, issue.50, pp.20048-53, 2011.
DOI : 10.1073/pnas.1114483108

A. Bommi-reddy, I. Almeciga, J. Sawyer, C. Geisen, W. Li et al., Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen, Proceedings of the National Academy of Sciences, vol.105, issue.43, pp.16484-16493, 2008.
DOI : 10.1073/pnas.0806574105

T. Hsu, Complex cellular functions of the von Hippel???Lindau tumor suppressor gene: insights from model organisms, Oncogene, vol.63, issue.18, pp.2247-57, 2012.
DOI : 10.1002/ajmg.1320490104

V. Haase, The VHL tumor suppressor in development and disease: Functional studies in mice by conditional gene targeting, Seminars in Cell & Developmental Biology, vol.16, issue.4-5, pp.564-74, 2005.
DOI : 10.1016/j.semcdb.2005.03.006

E. Rankin, J. Tomaszewski, and V. Haase, Renal Cyst Development in Mice with Conditional Inactivation of the von Hippel-Lindau Tumor Suppressor, Cancer Research, vol.66, issue.5, pp.2576-83, 2006.
DOI : 10.1158/0008-5472.CAN-05-3241

I. Frew, C. Thoma, S. Georgiev, A. Minola, M. Hitz et al., pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation, The EMBO Journal, vol.24, issue.12, pp.1747-57, 2008.
DOI : 10.1038/emboj.2008.96
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2435131

L. Fu, G. Wang, M. Shevchuk, D. Nanus, and L. Gudas, Generation of a Mouse Model of Von Hippel-Lindau Kidney Disease Leading to Renal Cancers by Expression of a Constitutively Active Mutant of HIF1??, Cancer Research, vol.71, issue.21, pp.6848-56, 2011.
DOI : 10.1158/0008-5472.CAN-11-1745

H. Shen, A. Adem, K. Ylaya, A. Wilson, M. He et al., Deciphering von Hippel-Lindau (VHL/Vhl)-Associated Pancreatic Manifestations by Inactivating Vhl in Specific Pancreatic Cell Populations, PLoS ONE, vol.15, issue.4, p.4897, 2009.
DOI : 10.1371/journal.pone.0004897.s001